Is Size All That Matters? New Predictors of Complications and Bleeding in Renal Angiomyolipoma

References

• Bhatt JR, Richard PO, Kim NS, et al. Natural history of Renal Angiomyolipoma (AML): most patients with large AMLs >4cm can be offered active surveillance as an initial management strategy. Eur Urol. 2016;70(1):85–90. doi:10.1016/j.eururo.2016.01.048
   PubMed Web of Science ®Google Scholar
• Bardin F, Chevallier O, Bertaut A, et al. Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction. Quant Imaging Med Surg. 2017;7(1):8–23. doi:10.21037/qims.2017.01.02
   PubMed Web of Science ®Google Scholar
• Fernández-Pello S, Hora M, Kuusk T, et al. Management of sporadic renal angiomyolipomas: a systematic review of available evidence to guide recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. Eur Urol Oncol. 2020;3(1):57–72. doi:10.1016/j.euo.2019.04.005
   PubMed Web of Science ®Google Scholar
• Nozadze G, Larsen SB, Heerwagen S, Juhl Jensen R, Lönn L, Røder MA. Selective arterial embolization of renal angiomyolipomas: a 10-year experience. BJUI Compass. 2022;3(1):86–92. doi:10.1002/bco2.107
   PubMedGoogle Scholar
• Murray TE, Doyle F, Lee M. Transarterial embolization of angiomyolipoma: a systematic review. J Urol. 2015;194(3):635–639. doi:10.1016/j.juro.2015.04.081
   PubMed Web of Science ®Google Scholar
• Ramon J, Rimon U, Garniek A, et al. Renal angiomyolipoma: long-term results following selective arterial embolization. Eur Urol. 2009;55(5):1155–1162. doi:10.1016/j.eururo.2008.04.025
   PubMed Web of Science ®Google Scholar
• Seyam RM, Alkhudair WK, Kattan SA, Alotaibi MF, Alzahrani HM, Altaweel WM. The risks of renal angiomyolipoma: reviewing the evidence. J Kidney Cancer VHL. 2017;4(4):13–25. doi:10.15586/jkcvhl.2017.97
   PubMedGoogle Scholar
• Makki A, Graumann O, Høyer S, et al. Cryoablation of renal angiomyolipoma: an evaluation of safety and efficacy. J Endourol. 2017;31(11):1117–1122. doi:10.1089/end.2017.0376
   PubMed Web of Science ®Google Scholar
• Vos N, Oyen R. Renal angiomyolipoma: the good, the bad, and the ugly. J Belg Soc Radiol. 2018;102(1):41. doi:10.5334/jbsr.1536
   PubMed Web of Science ®Google Scholar
• Urology EAo. EAU guidelines - renal cell carcinoma. 3.4.5. 2022.
   Google Scholar
• Abouelkheir RT, El-Ksas M, Abdel Fattah S, Amer T, El-Diasty T. Efficacy and safety of selective renal arterial embolization in renal angiomyolipoma: a prospective single-center study. Egypt J Radiol Nuclear Med. 2022;53(1):165. doi:10.1186/s43055-022-00848-3
   Web of Science ®Google Scholar
• Prigent F-V, Guillen K, Comby P-O, et al. Selective arterial embolization of renal angiomyolipomas with a N-butyl cyanoacrylate-lipiodol mixture: efficacy, safety, short- and mid-term outcomes. J Clin Med. 2021;10(18):4062. doi:10.3390/jcm10184062
   PubMed Web of Science ®Google Scholar
• Wang C, Li X, Peng L, Gou X, Fan J. An update on recent developments in rupture of renal angiomyolipoma. Medicine. 2018;97(16):e0497. doi:10.1097/md.0000000000010497
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Fishman EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. J Urol. 1986;135(6):1121–1124. doi:10.1016/s0022-5347(17)46013-7
   PubMed Web of Science ®Google Scholar
• Kuusk T, Biancari F, Lane B, et al. Treatment of renal angiomyolipoma: pooled analysis of individual patient data. BMC Urol. 2015;15(1):123. doi:10.1186/s12894-015-0118-2
   PubMedGoogle Scholar
• Restrepo JCA, Millan DAC, Sabogal CAR, Bernal AFP, Donoso WD. New trends and evidence for the management of renal angiomyolipoma: a comprehensive narrative review of the literature. J Kidney Cancer VHL. 2022;9(1):33–41. doi:10.15586/jkcvhl.v9i1.177
   PubMed Web of Science ®Google Scholar
• Thompson MM, Bell PR. ABC of arterial and venous disease. Arterial aneurysms. BMJ. 2000;320(7243):1193–1196. doi:10.1136/bmj.320.7243.1193
   PubMedGoogle Scholar
• Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology. 2002;225(1):78–82. doi:10.1148/radiol.2251011477
   PubMed Web of Science ®Google Scholar
• Chaiyasoot W, Yodying J, Limsiri T. Selective arterial embolization of renal angiomyolipoma: efficacy, tumor volume reduction and complications. Siriraj Med J. 2021;73(5):337–343. doi:10.33192/Smj.2021.44
   Google Scholar
• Bauman TM, Potretzke AM, Wright AJ, Vetter JM, Potretzke TA, Figenshau RS. Patient and nonradiographic tumor characteristics predicting lipid-poor angiomyolipoma in small renal masses: introducing the BEARS index. Investig Clin Urol. 2017;58(4):235–240. doi:10.4111/icu.2017.58.4.235
   PubMed Web of Science ®Google Scholar
• Potretzke AM, Potretzke TA, Bauman TM, et al. Computed tomography and magnetic resonance findings of fat-poor angiomyolipomas. J Endourol. 2017;31(2):119–128. doi:10.1089/end.2016.0219
   PubMed Web of Science ®Google Scholar
• Xu X-F, Hu X-H, Zuo Q-M, Zhang J, Xu H-Y, Zhang Y. A scoring system based on clinical features for the prediction of sporadic renal angiomyolipoma rupture and hemorrhage. Medicine. 2020;99(20). doi:10.1097/MD.0000000000020167
   Web of Science ®Google Scholar
• Rimon U, Duvdevani M, Garniek A, et al. Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding. Clin Radiol. 2006;61(6):520–526. doi:10.1016/j.crad.2006.02.003
   PubMed Web of Science ®Google Scholar
• Andersen PE, Thorlund MG, Wennevik GE, Pedersen RL, Lund L. Interventional treatment of renal angiomyolipoma: immediate results and clinical and radiological follow-up of 4.5 years. Acta Radiologica Open. 2015;4(7):2058460115592442. doi:10.1177/2058460115592442
   Google Scholar
• Li M, Zhou Y, Chen C, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi:10.1186/s13023-019-1012-x
   PubMed Web of Science ®Google Scholar
• Wang W, Guo G, Shi G, et al. A multi-centric study assessing safety and efficacy of everolimus in adult Chinese patients with tuberous sclerosis complex associated renal angiomyolipomas. Original Research. Front Oncol. 2022;12. doi:10.3389/fonc.2022.871723
   Web of Science ®Google Scholar
• Geynisman DM, Kadow BT, Shuch BM, et al. Sporadic angiomyolipomas growth kinetics while on everolimus: results of a phase II trial. J Urol. 2020;204(3):531–537. doi:10.1097/JU.0000000000001065
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS One. 2017;12(8):e0180939. doi:10.1371/journal.pone.0180939
   PubMed Web of Science ®Google Scholar